Phase II Study of 2-Chlorodeoxyadenosine (2CDA) Followed by Rituximab in Hairy Cell Leukemia
Latest Information Update: 21 May 2024
At a glance
- Drugs Cladribine (Primary) ; Rituximab (Primary)
- Indications Hairy cell leukaemia
- Focus Adverse reactions; Therapeutic Use
- 16 May 2024 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.
- 16 May 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Jun 2025.
- 22 May 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2024.